Literature DB >> 27090359

Brief Report: Alternative Splicing of Extra Domain A (EIIIA) of Fibronectin Plays a Tissue-Specific Role in Hematopoietic Homeostasis.

Alessandro Malara1,2, Cristian Gruppi1, Giuseppe Celesti3, Bina Romano4, Luigi Laghi3, Luigi De Marco5, Andrés F Muro6, Alessandra Balduini1,2,7.   

Abstract

Fibronectin (FN) is a major extracellular matrix protein implicated in cell adhesion and differentiation in the bone marrow (BM) environment. Alternative splicing of FN gene results in the generation of protein variants containing an additional EIIIA domain that sustains cell proliferation or differentiation during physiological or pathological tissue remodeling. To date its expression and role in adult hematopoiesis has not been explored. In our research, we demonstrate that during physiological hematopoiesis a small fraction of BM derived FN contains the EIIIA domain and that mice constitutively including (EIIIA(+/+) ) or excluding (EIIIA(-/-) ) the EIIIA exon present comparable levels of hematopoietic stem cells, myeloid and lymphoid progenitors within BM. Moreover, only minor alterations were detected in blood parameters and in hematopoietic frequencies of BM granulocytes/monocytes and B cells. As opposed to other tissues, unique compensatory mechanisms, such as increased FN accumulation and variable expression of the EIIIA receptors, Toll like receptor-4 and alpha9 integrin subunit, characterized the BM of these mice. Our data demonstrate that FN is a fundamental component of the hematopoietic tissue and that the EIIIA exon may play a key role in modulating hematopiesis in conditions of BM stress or diseases. Stem Cells 2016;34:2263-2268.
© 2016 AlphaMed Press.

Entities:  

Keywords:  Alternative splicing; Bone marrow; Fibronectin; Hematopoiesis

Mesh:

Substances:

Year:  2016        PMID: 27090359     DOI: 10.1002/stem.2381

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  8 in total

1.  Alternatively spliced fibronectin extra domain A is required for hemangiogenic recovery upon bone marrow chemotherapy.

Authors:  Alessandro Malara; Cristian Gruppi; Giuseppe Celesti; Vittorio Abbonante; Gianluca Viarengo; Luigi Laghi; Luigi De Marco; Andrés F Muro; Alessandra Balduini
Journal:  Haematologica       Date:  2017-11-16       Impact factor: 9.941

Review 2.  The determinants of alternative RNA splicing in human cells.

Authors:  Tatsiana V Ramanouskaya; Vasily V Grinev
Journal:  Mol Genet Genomics       Date:  2017-07-13       Impact factor: 3.291

Review 3.  The extracellular matrix of hematopoietic stem cell niches.

Authors:  Cornelia Lee-Thedieck; Peter Schertl; Gerd Klein
Journal:  Adv Drug Deliv Rev       Date:  2021-11-25       Impact factor: 15.470

Review 4.  The role of extracellular matrix stiffness in megakaryocyte and platelet development and function.

Authors:  Orly Leiva; Catherine Leon; Seng Kah Ng; Pierre Mangin; Christian Gachet; Katya Ravid
Journal:  Am J Hematol       Date:  2018-01-12       Impact factor: 10.047

Review 5.  Alternative Splicing in the Hippo Pathway-Implications for Disease and Potential Therapeutic Targets.

Authors:  Sean Porazinski; Michael Ladomery
Journal:  Genes (Basel)       Date:  2018-03-13       Impact factor: 4.096

6.  EDA fibronectin-TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis.

Authors:  Alessandro Malara; Cristian Gruppi; Vittorio Abbonante; Daniele Cattaneo; Luigi De Marco; Margherita Massa; Alessandra Iurlo; Umberto Gianelli; Carlo L Balduini; Maria E Tira; Andrès F Muro; Anil K Chauhan; Vittorio Rosti; Giovanni Barosi; Alessandra Balduini
Journal:  J Exp Med       Date:  2019-02-07       Impact factor: 14.307

Review 7.  Fibronectin and Its Receptors in Hematopoiesis.

Authors:  Franziska Wirth; Alexander Lubosch; Stefan Hamelmann; Inaam A Nakchbandi
Journal:  Cells       Date:  2020-12-18       Impact factor: 6.600

8.  Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression.

Authors:  Alessandro Malara; Cristian Gruppi; Margherita Massa; Maria Enrica Tira; Vittorio Rosti; Alessandra Balduini; Giovanni Barosi
Journal:  Front Oncol       Date:  2022-09-21       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.